Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIR-T Mesothelin
- Development stage
- Preclinical
- Lead developer
- Angeles Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
SIR-T Mesothelin is an autologous cell therapy candidate being developed by Angeles Therapeutics for the treatment of solid tumors that express mesothelin. The therapy utilizes the company's proprietary Synthetic Immune Receptor (SIR) platform, specifically the SIR-T modality, which is engineered to provide T cells with a synthetic receptor that mimics the natural T-cell receptor (TCR) complex. This design is intended to achieve more physiological T-cell activation, enhanced metabolic fitness, and improved persistence within the immunosuppressive tumor microenvironment compared to traditional CAR-T therapies. Mesothelin is a cell-surface glycoprotein that is highly expressed in several aggressive malignancies, including mesothelioma, ovarian cancer, and pancreatic adenocarcinoma, making it a viable target for directed immunotherapy. SIR-T Mesothelin is currently undergoing IND-enabling studies.
- Other names
- SIR-T Mesothelin
02
Targets
Mesothelin
Beyond the preview
Go deeper on SIR-T Mesothelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIR-T Mesothelin.